Project Grant R01AG087191

Award Date 7/15/24
Completion Date 4/30/29
Dollars Obligated $2.5M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
This $407,000 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by the University of Texas Rio Grande Valley (UTRGV) to investigate the relationship between HIV infection and the onset and progression of Alzheimer's disease (AD) using AD mouse models infected with a chimeric HIV strain. The central hypothesis is that HIV may accelerate the development of cognitive decline in AD. The 2-year study will conduct longitudinal behavioral,...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $630,905 to the University of Wisconsin-Madison to explore the role of the gut microbiome-derived metabolite imidazole propionate (IMP) in the progression of Alzheimer's disease (AD) and related dementias (ADRD). The central hypothesis is that IMP modulates AD and ADRD pathology by altering vascular endothelial function and blood-brain barrier permeability. The research will...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,550,462 to support a 5-year cross-sectional, longitudinal, and observational study investigating the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American individuals living with HIV. The project aims to enroll 120 participants with HIV (60 with and 60 without the APOE E4 allele) and 80 demographically...
The National Institute on Aging (NIA) awarded a $856,580 Project Grant (CFDA 93.866 - Aging Research) to the University of Massachusetts Lowell to elucidate the microbial origins of Alzheimer's disease and related dementias (AD/ADRD) in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort. The project will generate longitudinal gut microbiome and serum metabolomic profiles for approximately 2,800 HCHS/SOL participants to investigate the role of the gut microbiome in AD/ADRD...
This Project Grant award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a comprehensive study to determine the prevalence and clinical characteristics of mild cognitive impairment (MCI) and Alzheimer's-related dementia (ADRD) among older adults living with HIV in Uganda. The $1,103,953 award, which began on Sep 15, 2024 and runs through Aug 31, 2025, will fund the following key activities: Comprehensive neuropsychological assessments among 600 older...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,161,154 to the University of South Carolina to conduct research aimed at addressing HIV-1-associated neurocognitive disorders (HAND) in older adults. The key objectives are to: 1) Develop "dendritic spine-targeted" therapeutics, such as the isoflavandiol estrogen S-equol and a specific estrogen B-receptor agonist, to restore synaptodendritic integrity and mitigate neurocognitive...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to evaluate the effects of poverty alleviation policies on the risk and disparities of Alzheimer's disease and related dementias (AD/ADRD). The $131,813 award to Trustees of Boston University, awarded on May 1, 2025, will support a research program with two key objectives: In the K99 phase, the researcher will integrate Health and Retirement Study (HRS) and Medicare data to quantify state-level...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $768,131 over 5 years to the University of California, San Diego (UCSD) to investigate the role of the TREM2 protein in Alzheimer's disease pathogenesis among people living with HIV. The project aims to delineate the specific mechanisms by which HIV infection may alter TREM2 function, potentially exacerbating neurodegeneration and inflammation and accelerating...
This $124,526 Project Grant was awarded by the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research. The grant will support a research project at the University of Florida to examine disparities in the risk of dementia among people living with HIV (PWH) aged 50 and older. The project will leverage real-world data sources, including electronic health records and claims data, linked with social determinants of health data, to develop machine learning-based prediction models for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to the University of South Florida will support research to determine the role of gut-derived microRNAs (miRNAs) in age-related cognitive decline and Alzheimer's disease and related dementias (ADRD). The $849,904 award, effective September 30, 2024 through August 31, 2026, will fund studies to identify unique miRNA signatures in the blood of older adults with mild cognitive impairment (MCI) and dementia...

VITAMIN D AND GUT MICROBIOTA AND DEMENTIA RISK IN OLDER ADULTS WITH CHRONIC HIV INFECTION AND DEMOGRAPHICALLY MATCHED COMMUNITY CONTROLS - THE GLOBAL BURDEN OF ALZHEIMER'S DEMENTIA AND RELATED DISORDERS (ADRD) IS GROWING IN TANDEM WITH THE DEMOGRAPHIC TRANSITION TOWARD AN AGED SOCIETY WHERE OLDER ADULTS 65 YEARS OLD THAT ARE MORE VULNERABLE TO ADRD CONSTITUTE A LARGER SHARE OF THE GENERAL POPULATION. THE FASTEST INCREASE IN ADRD AND AGING ADULTS IS OCCURRING IN SUB-SAHARAN AFRICA WHERE PERSONS 50+ YEARS OLD LIVING WITH CHRONIC HIV INFECTION (OPH+) ON COMBINATION ANTIRETROVIRAL THERAPY REPRESENT AS MUCH AS 20% OF OLDER ADULTS IN SOME SETTINGS. OPH+ ARE AT FURTHER RISK OF ADVERSE COGNITIVE OUTCOMES AND POTENTIALLY ADRD DUE TO HIV- AND HIV-TREATMENT-RELATED BIOLOGICAL AND PSYCHOSOCIAL RISKS SUCH AS GUT-MICROBIAL DYSBIOSIS, MALNUTRITION, COMORBID NON-COMMUNICABLE DISEASES AND FRAILTY. IN REGIONS WITH GENERALIZED HIV-EPIDEMIC, THESE MULTIPLE RISKS OVERLAP PROVIDING BOTH VARIATION AND INTENSITY OF CO-OCCURRING POTENTIALLY CAUSAL ADRD RISK FACTORS IN THE AGING POPULATION AND THE IMPLICATION FOR ADRD PREVALENCE RATE AND NEW ONSET ADRD IS UNKNOWN. PRESENTLY, MODIFIABLE TARGETS OF ADRD ARE FEW ALONG WITH UNDERSTANDING OF THE MECHANISMS UNDERLYING POTENTIAL ADRD RISK FACTORS. TO INFORM STRATEGIES FOR PREVENTING THE ONSET AND PROGRESSION OF ADRD IN OLDER POPULATIONS, WE FOCUS ON GUT MICROBIAL DYSBIOSIS AND VITAMIN D DEFICIENCY (VDD), INCLUDING LEVELS OF BIOACTIVE VD, AS MODIFIABLE ADRD DETERMINANTS. BOTH RISK FACTORS INCREASE WITH ADVANCING AGE AND ARE MAGNIFIED FURTHER AMONG OPH+. SPECIFICALLY, WE INVESTIGATE HOW GUT-MICROBIAL DYSBIOSIS AND LOW VITAMIN D IMPACT INFLAMMATION (I.E., SYSTEMIC, INTESTINAL AND NEUROINFLAMMATION) AND THUS ADRD RISK IN OLDER ADULTS WITH AND WITHOUT CHRONIC HIV. WE TEST THE HYPOTHESIS THAT: A) GUT DYSBIOSIS AND VDD WILL BE ASSOCIATED WITH COGNITIVE DYSFUNCTION, HIGHER ADRD RISK, AND LOWER NEUROPSYCHOLOGICAL STATUS AND B) THE EFFECTS OF DYSBIOSIS AND VDD ON ADRD RISK IS MEDIATED BY INFLAMMATION AND C) EACH RISK FACTOR'S RELATIONSHIP TO ADRD WILL BE MODIFIED BY COMORBID CHRONIC HIV INFECTION. OUR SPECIFIC AIMS INCLUDE: 1. A. TO QUANTIFY THE INDEPENDENT ASSOCIATION BETWEEN EACH RISK FACTOR (GUT DYSBIOSIS AND VDD) AND ADRD. 1. B. TO TEST WHETHER INFLAMMATION MEDIATES THE EFFECTS OF EACH RISK FACTOR (DYSBIOSIS AND VDD) ON ADRD. 2. TO QUANTIFY THE ADVERSE SYNERGY OF GUT DYSBIOSIS AND VDD IN RELATIONSHIP TO INFLAMMATION. 3. TO EXAMINE WHETHER HIV STATUS IS A MODIFIER OF THE RELATIONSHIP OF DYSBIOSIS AND VDD TO ADRD RISK. OVERALL IMPACT: WE WILL DELINEATE HOW DISRUPTIONS OF VD METABOLOME AND THE GUT-BRAIN AXIS CONTRIBUTE TO HIGHER ADRD RATE THROUGH IMMUNE DYSFUNCTION IN A LARGE SAMPLE OF OLDER ADULTS. THE JOINT INTERROGATION OF THESE RISK FACTORS IS NOVEL AND DIRECTLY ENHANCES TRANSLATIONAL UTILITY OF THIS WORK SINCE POCKETS OF HIGHER ADRD RISK WILL BE IDENTIFIED AND USED TO INFORM TAILORING OF FUTURE MULTIMODAL INTERVENTIONS BASED ON DIFFERENCES IN VD METABOLOME, GMD, SEVERITY OF INFLAMMATION, AND COMORBID HIV-INFECTION.

Posted 7/11/24, 12:00 AM